News coverage about Apricus Biosciences (NASDAQ:APRI) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Apricus Biosciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.2222116893884 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research firms recently commented on APRI. Zacks Investment Research lowered Apricus Biosciences from a “buy” rating to a “sell” rating in a research report on Tuesday, November 7th. HC Wainwright reissued a “buy” rating and set a $4.50 price target on shares of Apricus Biosciences in a research report on Friday, November 3rd.
Apricus Biosciences (APRI) traded up $0.01 during trading on Tuesday, reaching $1.59. The company had a trading volume of 73,700 shares, compared to its average volume of 677,215. Apricus Biosciences has a 12-month low of $0.86 and a 12-month high of $4.07.
Apricus Biosciences (NASDAQ:APRI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same quarter in the prior year, the business earned ($0.19) earnings per share. analysts predict that Apricus Biosciences will post -0.6 earnings per share for the current fiscal year.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.